NAMS peer analysis
NewAmsterdam Pharma (NAMS) against its competitors: price, today's move, 1-year return and market value side by side.
NAMS and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ABOS Acumen Pharmaceuticals | $0.23 | 6.74% | -89.25% | – |
| AMLX Amylyx Pharmaceuticals | $30.16 | 9.20% | 123.04% | – |
| ATHE Alterity Therapeutics | $2.22 | -9.02% | -43.08% | $42.39M |
| BIOA BioAge Labs | $5.37 | -3.01% | -29.07% | – |
| CRVO CervoMed | $1.45 | -7.05% | -80.25% | – |
| DNLI Denali Therapeutics | $20.16 | 2.23% | 34.72% | $3.21B |
| MDGL Madrigal Pharma | $403.28 | 0.79% | -15.31% | $9.31B |
| MTVA MetaVia | $1.09 | -18.66% | -90.09% | – |
| SEPN Septerna | $48.78 | 3.02% | 155.15% | – |
| VKTX Viking Therapeutics | $26.80 | 3.92% | -26.21% | $3.43B |
| NAMS NewAmsterdam Pharma | $18.70 | -1.01% | -50.47% | – |
- NAMS's peers: ABOS (Acumen Pharmaceuticals), AMLX (Amylyx Pharmaceuticals), ATHE (Alterity Therapeutics), BIOA (BioAge Labs), CRVO (CervoMed), DNLI (Denali Therapeutics), MDGL (Madrigal Pharma), MTVA (MetaVia).
Updated 2026-11-07 11:55 UTC